ERBB2 and ductal breast carcinoma in situ: A small prospective phase II single-arm study has also demonstrated that lapatinib (a tyrosine kinase inhibitor) interrupts the HER2/neu and epidermal growth factor receptor pathways, and significantly decreases the expressions of pHER2 and pERK1 in patients with HER2-positive DCIS.